Barriers to Clinical Trials for Non-Muscle Invasive Bladder Cancer

Ashish M. Kamat, MD, articulates the discrepancies in the American Urological Association and European Association of Urology bladder cancer treatment guidelines, challenges in defining a risk-stratification scale for the disease, knowledge gaps regarding BCG failure, and other factors that hinder the urological community’s ability to design quality clinical trials for non-muscle invasive bladder cancer.

Read More